RESUMO
Huntington's disease (HD) is an autosomal neurodegenerative disease that involves movement disorders, cognitive impairments, and psychiatric symptoms. It is characterized by regionally selective cortical degeneration that proceeds from posterior to anterior cortical region which explains its heterogeneity. At present, the psychiatric symptoms of HD are mostly managed by antidepressant such as selective serotonin reuptake inhibitors or selective nor-epinephrine reuptake inhibitors, and atypical antipsychotics. Currently, there are no efficient pharmacological treatment available for HD. Thus, in order to avoid this void in effective pharmacotherapy, further supplemental and alternative approaches are being explored for the management of problems associated with HD. A literature review was performed using the databases PubMed and Google Scholar identifying clinical studies that were set to ameliorate the symptoms associated with HD. On critical analysis, it was found that alternative treatment modalities like music therapy, video games, Yoga, Physical therapy, and exercise-based programs have a potential and possible role in improving the symptoms of HD at varied degrees.
Assuntos
Disfunção Cognitiva , Doença de Huntington , Doenças Neurodegenerativas , Humanos , Doença de Huntington/diagnóstico , Doença de Huntington/tratamento farmacológico , Exercício FísicoRESUMO
OBJECTIVE: After MRI studies suggested the efficacy of ethyl-EPA in reducing the progressive brain atrophy in Huntington disease (HD), trials were conducted to test its efficacy as a treatment for HD. Trials that continued for 6 months did not find any significant improvement, urging discontinuation of the drug. However, trials that continued for 12 months indicated improvement of motor functions in these patients. METHODS: We searched 12 electronic databases to find randomised clinical trials relevant to our inclusion criteria. After screening, only five papers were included. Continuous and binary variables were analysed to compute the pooled mean difference (MD) and risk ratio (RR), respectively. Quality effect model meta-analysis was used as a post hoc analysis for studies at 12 months. FINDINGS: Meta-analysis indicated that ethyl-eicosapentaenoic acid (EPA) has no significant effect on any scale of HD at 6 months. At 12 months, two studies suggested significant improvements of the Total Motor Score and Total Motor Score-4 in both fixed and quality effect models [MD = -2.720, 95% CI (-4.76, -.68), p = 0.009; MD = -2.225, 95% CI (-3.842, -0.607), p = 0.007], respectively. Maximal chorea score showed significant results [MD = -1.013, 95% CI (-1.793, -0.233), p = 0.011] in only fixed-effect model, while no improvement was detected for Stroop colour naming test or symbol digit modality. CONCLUSION: Meta-analysis indicated a significant improvement of motor scores only after 12 months. These results should be interpreted cautiously because only two studies had assessed the efficacy of ethyl-EPA after 12 months with one of them having a 6-month open-label phase.
Assuntos
Ácido Eicosapentaenoico/análogos & derivados , Doença de Huntington/tratamento farmacológico , Ácido Eicosapentaenoico/uso terapêutico , Humanos , Doença de Huntington/diagnóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
Huntington's disease (HD) patients and families deserve expert treatment and care throughout their lives, but uniformity in functional diagnosis and treatment was lacking. In the aim of reaching this uniformity on day-to-day treatment and care offered by multidisciplinary outreach teams from Dutch long term care facilities for ambulatory HD patients, a consensus trajectory was started to harmonise our care programme with international standards and within the country. The consensus statements, given as supplementary material, should lead to expert treatment and care for HD families throughout the Netherlands and this manuscript should contribute and revitalise a global discussion on standards of treatment and care.
Assuntos
Instituições de Assistência Ambulatorial/normas , Assistência Ambulatorial/normas , Prestação Integrada de Cuidados de Saúde/normas , Doença de Huntington/diagnóstico , Doença de Huntington/terapia , Consenso , Humanos , Assistência de Longa Duração/normas , Países BaixosRESUMO
BACKGROUND: Case studies of people with Huntington's disease (HD) report that music therapy provides a range of benefits that may improve quality of life; however, no robust music therapy assessment tools exist for this population. OBJECTIVE: Develop and conduct preliminary psychometric testing of a music therapy assessment tool for patients with advanced HD. METHODS: First, we established content and face validity of the Music Therapy Assessment Tool for Advanced HD (MATA-HD) through focus groups and field testing. Second, we examined psychometric properties of the resulting MATA-HD in terms of its construct validity, internal consistency, and inter-rater and intra-rater reliability over 10 group music therapy sessions with 19 patients. RESULTS: The resulting MATA-HD included a total of 15 items across six subscales (Arousal/Attention, Physical Presentation, Communication, Musical, Cognition, and Psychological/Behavioral). We found good construct validity (r ≥ 0.7) for Mood, Communication Level, Communication Effectiveness, Choice, Social Behavior, Arousal, and Attention items. Cronbach's α of 0.825 indicated good internal consistency across 11 items with a common focus of engagement in therapy. The inter-rater reliability (IRR) Intra-Class Coefficient (ICC) scores averaged 0.65, and a mean intra-rater ICC reliability of 0.68 was obtained. Further training and retesting provided a mean of IRR ICC of 0.7. CONCLUSION: Preliminary data indicate that the MATA-HD is a promising tool for measuring patient responses to music therapy interventions across psychological, physical, social, and communication domains of functioning in patients with advanced HD.
Assuntos
Doença de Huntington/terapia , Musicoterapia , Psicometria/instrumentação , Inquéritos e Questionários/normas , Adulto , Atenção , Feminino , Grupos Focais , Humanos , Doença de Huntington/diagnóstico , Doença de Huntington/psicologia , Masculino , Pessoa de Meia-Idade , Musicoterapia/métodos , Projetos Piloto , Psicometria/estatística & dados numéricos , Qualidade de Vida , Reprodutibilidade dos TestesRESUMO
The causes of weight loss in Huntington's disease (HD) are not entirely clear. The aim was to identify risk factors that are associated with a loss of metabolically active tissues, i.e. fat-free mass. A consecutive cohort of non-diabetic HD participants (manifest HD, n = 43; CAG: mean 43.6.0 ± 3.6; preHD, n = 10; CAG: mean 41.4 ± 1.4) and 36 healthy controls was recruited. Twenty-five HD participants were early-stage HD (UHDRS Total Functional Capacity [TFC] stages I and II), 12 mid-stage HD (TFC stage III), and 6 participants were in late-stage HD (TFC stages IV and V). Food intake, basic metabolic rate and glucose homeostasis were assessed. In addition, fat-free mass was determined using bioelectric impedance analysis, and leptin, insulin and ghrelin as key metabolic regulators. Sex ratio and age were similar in HD participants (71 % women; age 50.6 ± 10.9) and controls (66 % women; age 46.4 ± 14.5). Body mass index (BMI) was lower in HD participants than controls (median 24.1 vs. 25.9, p = 0.04). However, fat-free mass and basic metabolic rate were not statistically different between groups and showed no association with disease burden. In controls and HD participants, leptin was the most important predictor of fat-free mass. While BMI was lower in HD participants, fat-free mass was similar to controls with leptin as its most important predictor. Leptin levels and fat-free mass measurements using bioelectric impedance analysis may be good screening tools to identify HD patients at risk for weight loss.
Assuntos
Índice de Massa Corporal , Gorduras/metabolismo , Doença de Huntington/diagnóstico , Doença de Huntington/metabolismo , Adulto , Composição Corporal , Contagem de Células , Suplementos Nutricionais , Impedância Elétrica , Feminino , Humanos , Proteína Huntingtina , Doença de Huntington/genética , Linfócitos/patologia , Masculino , Pessoa de Meia-Idade , Proteínas do Tecido Nervoso/genética , Avaliação Nutricional , Valor Preditivo dos Testes , Repetições de Trinucleotídeos/genéticaRESUMO
BACKGROUND: Huntington's disease (HD) is a complex, single-gene inherited neurodegenerative condition resulting in symptoms that occur across a wide range of neurological domains, including cognitive, behavioral and motor. The benefits of regular physical activity for people with HD are widely recognized. However, a number of factors can prohibit sustained exercise and activity. The purpose of this trial is to explore the feasibility, acceptability and effectiveness of a physical activity intervention program targeted for people with early- to mid-stage HD. METHODS/DESIGN: The proposed trial is a single blind, multisite, exploratory, randomized controlled feasibility trial of a physical activity intervention. A total of 62 participants with genetically confirmed HD will be recruited. Each participant will be involved in the trial for 26 weeks. Participants will be randomized immediately following the baseline assessment into either a physical activity intervention or a social contact control intervention. The physical activity intervention is framed around self-determination theory placed within a broader behaviour change wheel framework. An HD-specific workbook and individual goal setting will be utilized over six 1:1 sessions, with interim telephone calls. All participants will be reassessed at 16 weeks following the baseline assessment, and then again at a final follow-up assessment 26 weeks later. At the end of the study, all participants will be offered a brief version of the alternative intervention, with one home visit and one follow-up telephone call. DISCUSSION: Engaging and supporting people with HD in a regular physical activity program raises a number of challenges. The physical activity intervention and the comparator social interaction intervention have been developed following consultation with people with HD and their families. Each are individually tailored and determined on individual needs and goals. The results from this trial will provide guidance for the development of definitive trials. TRIAL REGISTRATION: The trial was registered with ISRCTN ( http://www.isrctn.com/ISRCTN65378754) on 13 March 2014.
Assuntos
Terapia por Exercício/métodos , Doença de Huntington/terapia , Atividade Motora , Projetos de Pesquisa , Protocolos Clínicos , Europa (Continente) , Estudos de Viabilidade , Comportamentos Relacionados com a Saúde , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Doença de Huntington/diagnóstico , Doença de Huntington/genética , Doença de Huntington/fisiopatologia , Doença de Huntington/psicologia , Relações Interpessoais , Motivação , Autonomia Pessoal , Método Simples-Cego , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: Structural magnetic resonance imaging (MRI) of the brain could be a powerful tool for discovering early biomarkers in clinically presymptomatic carriers of the Huntington's disease gene mutation (preHD). So far, structural changes have been found mainly in preHD approaching the estimated motor onset of the disease (i.e., less than 15 years from onset), whereas structural findings in preHD far from the estimated motor onset have been inconclusive. OBJECTIVES: The aims of this study were to investigate the sensitivity of different methodological approaches to structural data in far-from-onset preHD (mean estimated time to motor onset = 21.4 years) and to explore the relationship between brain structure, clinical variables and cognition. METHODS: High-resolution MRI data at 3 T were obtained from 20 preHD individuals and 20 healthy participants and subsequently analyzed using voxel-based morphometry (VBM), cortical surface modeling and subcortical segmentation analysis techniques. RESULTS: VBM analyses did not reveal significant between-group differences, whereas cortical surface modeling and subcortical segmentation analyses showed significant regional cortical thinning and striatal changes in preHD compared to controls. Significant correlations were found between striatal structure, estimated time to motor onset and executive performance, whereas cortical changes were not significantly correlated with these parameters. CONCLUSION: These data suggest that a combined methodological approach to structural MRI data could increase the sensitivity for detecting subtle neurobiological changes in early preHD. As consistently shown across different methods, the association between striatal structure and clinical measures supports the notion that changes in striatal volume could represent a more robust marker of disease progression than cortical changes.
Assuntos
Encéfalo/patologia , Corpo Estriado/patologia , Doença de Huntington/patologia , Imageamento por Ressonância Magnética/métodos , Adulto , Doenças Assintomáticas , Cognição , Interpretação Estatística de Dados , Progressão da Doença , Feminino , Humanos , Doença de Huntington/diagnóstico , Masculino , Tálamo/patologiaRESUMO
BACKGROUND: Impaired selective attention in Huntington disease (HD) may manifest as difficulty in identifying a single target embedded among a series of distractors in rapid serial visual presentation tasks. METHOD: We used an attentional blink (AB) paradigm to examine whether attentional control is impaired in symptomatic HD. Fourteen HD patients and 13 age-matched healthy controls performed a rapid serial visual presentation task in which 2 targets (T1 and T2) and numerous distractors were presented in rapid succession. We assessed the accuracy of T1 identification and the AB (impaired T2 detection after the correct identification of T1). RESULTS: Among the HD patients, identification of T1 was significantly impaired and AB was significantly larger but not longer. The HD patients also made significantly more random errors. CONCLUSIONS: Frontostriatal or frontoparietal dysfunction is likely to compromise attentional control in HD, such that well-masked and rapidly presented target stimuli are difficult to detect and identify, especially as the difficulty level increases. Although we previously reported no AB deficits in presymptomatic HD, with manifest disease we found that the progressive frontoparietal cortical changes compromise attentional control mechanisms.
Assuntos
Atenção/fisiologia , Intermitência na Atenção Visual/fisiologia , Doença de Huntington/diagnóstico , Doença de Huntington/fisiopatologia , Estudos de Casos e Controles , Feminino , Humanos , Doença de Huntington/complicações , Masculino , Pessoa de Meia-Idade , Estimulação Luminosa/métodos , Desempenho Psicomotor/fisiologiaRESUMO
Huntington disease (HD) is an autosomal-dominant, incurable, progressive disorder that manifests with chorea and behavioral and cognitive impairment. The disease usually occurs during the fourth or fifth decade of life; however, it may present at any age. Clinical suspicion is confirmed by genetic testing. Death occurs, on average, 15 to 20 years after the onset of symptoms. Here we report about a Hispanic woman and her family who were affected by the disease; this case illustrates the role of cultural values and beliefs in the decision-making process, as well as the importance of the physician's cultural competency in fostering a trusting relationship that may lessen the burden of catastrophic diseases on individuals, families, and society at-large.
Assuntos
Doença de Huntington/diagnóstico , Medicina Tradicional , Mitologia , Bruxaria , Diversidade Cultural , Cultura , Feminino , Testes Genéticos , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Doença de Huntington/genética , Pessoa de Meia-IdadeRESUMO
Huntington disease (HD) is a fatal neurodegenerative disorder caused by expansion of a CAG repeat in the HD gene. Degeneration concentrating in the basal ganglia has been thought to account for the characteristic psychiatric symptoms, cognitive decline and motor dysfunction. However, the homeostatic control of emotions and metabolism are disturbed early in HD, and focused studies have identified a loss of orexin (hypocretin) neurons in the lateral hypothalamus in HD patients. There has been limited assessment of other hypothalamic cell populations that may be involved. In this study, we quantified the neuropeptide-expressing hypothalamic neurons known to regulate metabolism and emotion in patients with HD compared to healthy controls using unbiased stereological methods. We confirmed the loss of orexin-expressing neurons in HD and revealed substantial differences in the peptide expression of other neuronal populations in the same patients. Both oxytocin- and vasopressin-expressing neurons were decreased by 45 and 24%, respectively, while the number of cocaine- and amphetamine-regulated transcript (CART)-expressing neurons was increased by 30%. The increased expression of CART in the hypothalamus is consistent with a previous study showing increased CART levels in cerebrospinal fluid from HD patients. There was no difference in the numbers of neuropeptide Y-expressing neurons. These results show significant and specific alterations in the peptide expression of hypothalamic neurons known to regulate metabolism and emotion. They may be important in the development of psychiatric symptoms and metabolic disturbances in HD, and may provide potential targets for therapeutic interventions.
Assuntos
Doença de Huntington/metabolismo , Doença de Huntington/patologia , Hipotálamo/metabolismo , Hipotálamo/patologia , Neuropeptídeos/metabolismo , Humanos , Doença de Huntington/diagnóstico , Degeneração Neural/diagnóstico , Degeneração Neural/metabolismo , Degeneração Neural/patologia , Neurônios/metabolismo , Neurônios/patologiaRESUMO
AIMS: A family history of Huntington disease (HD) or receiving results of HD predictive genetic testing can influence individual well-being, family relationships, and social interactions in positive and negative ways. The aim of this study was to examine benefits reported by people with an HD family history or those who have undergone predictive HD testing, as well as the personal variables associated with perceived benefits. METHODS: Seventy-four of 433 people completing the International Response of a Sample Population to HD risk (I-RESPOND-HD) survey reported benefits. Knowledge and understanding was perceived as the most common benefit from participants in both groups. The next most frequent perceived benefits from a family history were connecting with others and achieving life meaning and insights. The next most common perceived benefits from genetic testing were life planning and social support. The least common perceived benefit for both groups was renewed hope and optimism. Older age and spirituality were significantly associated with benefits in both groups. CONCLUSIONS: Perceptions of benefit may not be as likely until later years in people with prodromal HD. A developed sense of spirituality is identified as a personal resource associated with the perception of benefit from genetic testing for HD. Associations among spirituality, perceived benefits, and other indicators of personal and family well-being may be useful in genetic counseling and health care of people with prodromal HD.
Assuntos
Saúde da Família , Predisposição Genética para Doença/psicologia , Testes Genéticos/psicologia , Doença de Huntington/psicologia , Satisfação do Paciente , Adaptação Psicológica , Adulto , Criança , Filho de Pais com Deficiência/psicologia , Tomada de Decisões , Feminino , Aconselhamento Genético , Humanos , Doença de Huntington/diagnóstico , Conhecimento , Masculino , Pessoa de Meia-Idade , Preconceito , Risco , Autoimagem , Apoio Social , Espiritualidade , Fatores de TempoRESUMO
During the last decade, the field of human genome research has gone through a phase of rapid discovery that has provided scientists and physicians with a wide variety of research tools that are applicable to important medical issues. We describe a true case of familial Huntington disease (HD) in which we modified personal details to protect patient's privacy, where the proband at risk preferred not to know his disease status but wanted to know the status in his unborn child. Once we found the father to be negative, the case raised an important ethical question regarding the management of this as well as future pregnancies. This article discusses the arguments for and against the right not to know of one's carrier status, as well as professional obligations in the context of withholding unwanted information that may have direct implications not only for the patient himself but also for other family members. HD has served as a model for many other adult onset genetic diseases in terms of carrier testing guidelines. Hence, we feel it is time to revisit the issue of prenatal testing for HD and consider updating the current recommendations regarding the patient's right to "genetic ignorance", or the right not to know genetic information.
Assuntos
Genômica , Nível de Saúde , Doença de Huntington/diagnóstico , Doença de Huntington/genética , Direitos do Paciente/ética , Diagnóstico Pré-Natal/ética , Adulto , Idade de Início , Tomada de Decisões , Ética Profissional , Feminino , Predisposição Genética para Doença , Guias como Assunto , Humanos , Doença de Huntington/epidemiologia , Fatores de RiscoRESUMO
Huntington's disease (HD) is a progressive neurogenetic disorder that has a 50% inheritance rate. The ability to have 100% confirmation of the illness became a reality with the discovery of the gene in 1993. The effect of confirmatory testing and the issues faced by the individual and the family facing diagnosis have not been addressed. The purpose of this research study was to explore the meaning of being diagnosed with HD using narrative inquiry. Ten participants, during the first year of diagnosis, were asked to tell their story of what it meant to be diagnosed with HD. A holistic-content approach was used for data analysis. An integrated narrative, "The Story of HD: Ripples From a Stone Skipping Across the Lake," was created from the stories. The stories were analyzed for plot, predicaments, protagonist, and antagonist. The predicaments of "discovering the existence of HD," "confirming the diagnosis of HD," "revealing the diagnosis to others," and "experiencing the reverberations of HD" served as the main chapters that formed the structure of the stories. Each predicament contains a set of themes that function as subheadings for the chapters. In the final chapter or epilogue, participants were asked to reflect on the meaning of being diagnosed with HD. The psychological impact of receiving a positive genetic diagnosis has implications for patients and their extended families. Nurses should develop their understanding of the role of genetics in healthcare today. Clinical evaluations of the effectiveness of treatments and assessment for changes in mood, behavior, and motor function are an essential part of nursing care. Advocacy and supportive roles must be incorporated into the patient visit. Patient education material on home safety, nutrition, medication management, and general health practices should be provided during the outpatient visits. Through the development of a more comprehensive role, the nurse can assist patients and families in finding the personal meaning of being diagnosed.
Assuntos
Adaptação Psicológica , Atitude Frente a Saúde , Doença de Huntington/diagnóstico , Doença de Huntington/psicologia , Atividades Cotidianas/psicologia , Adulto , Idoso , Efeitos Psicossociais da Doença , Família/psicologia , Feminino , Testes Genéticos/psicologia , Humanos , Doença de Huntington/genética , Masculino , Pessoa de Meia-Idade , Narração , Papel do Profissional de Enfermagem , Pesquisa Metodológica em Enfermagem , Defesa do Paciente , Educação de Pacientes como Assunto , Autorrevelação , Apoio SocialRESUMO
Huntington's disease (HD) is a neurodegenerative, autosomal dominant disease that manifests with a triad of symptom clusters including movement disorder, cognitive impairment and psychiatric symptoms. We present a patient with HD who, prior to developing neurological signs and symptoms, had been exposed to war trauma and had developed posttraumatic stress disorder. Fifteen years later he manifested with dysarthria, difficulties with swallowing and involuntary movement. What brought him to psychiatrist was a heteroanamnestically noticed change in personality with irritable mood, impulsivity, aggressive outbursts in behavior and delusional ideation. Therapy was stared with haloperidol, but patient developed severe extrapiramidal side effects. Subsequent treatment with olanzapine, diazepam and omega 3 fatty acids lead to mood stabilization and better impulse control with even some improvement in motoric symptoms. To our knowledge, this is the first case report on combat related PTSD as psychiatric disorder manifested prior to HD. We discuss a possible influence of psychological stress disorder on severity of psychiatric symptoms in the HD. The importance of personalized approach in both psychopharmacological and psychotherapeutical treatment of patients with HD is emphasized. If the influence of environmental stress on the psychiatric phenotype of the disease should be confirmed by clinical trials and further studies, both screening methods and interventions aimed to reduce psychological stress in carriers of Huntington gene could be considered.
Assuntos
Distúrbios de Guerra/diagnóstico , Distúrbios de Guerra/psicologia , Doença de Huntington/diagnóstico , Doença de Huntington/psicologia , Transtornos de Estresse Pós-Traumáticos/diagnóstico , Transtornos de Estresse Pós-Traumáticos/psicologia , Alelos , Antipsicóticos/uso terapêutico , Atrofia , Benzodiazepinas/uso terapêutico , Córtex Cerebral/patologia , Cromossomos Humanos Par 4/genética , Distúrbios de Guerra/genética , Distúrbios de Guerra/terapia , Terapia Combinada , Comorbidade , Diagnóstico Diferencial , Diazepam/uso terapêutico , Ácidos Graxos Ômega-3/uso terapêutico , Testes Genéticos , Humanos , Doença de Huntington/genética , Doença de Huntington/terapia , Imageamento por Ressonância Magnética , Masculino , Bulbo/patologia , Pessoa de Meia-Idade , Exame Neurológico , Olanzapina , Equipe de Assistência ao Paciente , Psicoterapia , Fatores de Risco , Meio Social , Transtornos de Estresse Pós-Traumáticos/genética , Transtornos de Estresse Pós-Traumáticos/terapia , Repetições de TrinucleotídeosRESUMO
OBJECTIVE: The striatum and its projections are thought to be the earliest sites of Huntington's disease (HD) pathology. This study aimed to investigate progression of striatal pathology in symptomatic HD using diffusion tensor imaging. METHOD: Diffusion weighted images were acquired in 18 HD patients and in 17 healthy controls twice, 1 year apart. Mean diffusivity (MD) was calculated in the caudate, putamen, thalamus and corpus callosum, and compared between groups. In addition, caudate width was measured using T1 high resolution images and correlated with caudate MD. Correlation analyses were also performed in HD between caudate/putamen MD and clinical measures. RESULTS: MD was significantly higher in the caudate and putamen bilaterally for patients compared with controls at both time points although there were no significant MD differences in the thalamus or corpus callosum. For both groups, MD did not change significantly in any region from baseline to year 1. There was a significant negative correlation between caudate width and MD in patients at baseline but no correlation between these parameters in controls. There was also a significant negative correlation between Mini-Mental State Examination scores and caudate MD and putamen MD at both time points in HD. CONCLUSIONS: It appears that microstructural changes influence cognitive status in HD. Although MD was significantly higher in HD compared with controls at both time points, there were no longitudinal changes in either group. This finding does not rule out the possibility that MD could be a sensitive biomarker for detecting early change in preclinical HD.
Assuntos
Corpo Estriado/patologia , Imagem de Tensor de Difusão , Doença de Huntington/diagnóstico , Processamento de Imagem Assistida por Computador , Adulto , Núcleo Caudado/patologia , Corpo Caloso/patologia , Dominância Cerebral/fisiologia , Feminino , Humanos , Doença de Huntington/patologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Degeneração Neural/diagnóstico , Degeneração Neural/patologia , Exame Neurológico , Putamen/patologia , Valores de Referência , Estatística como Assunto , Tálamo/patologiaRESUMO
Huntington's disease is characterised by a complex set of motor, neuropsychologic and psychiatric symptoms which start slowly and progress over many years to a state of complete dependency. The symptomatic treatment during the ambulatory years is divers. In the northern part of the Netherlands coordinated multidisciplinary care is offered to patients diagnosed with Huntington's disease. A team of a neurologist, psychologist, occupational therapist, speech and language therapist, social worker and nursing home doctor monitors the patient and companion on a half-year basis and provide them with a plan of care. A case manager coordinates the plan of care in the dwelling place of the patient. In this article this type of care is outlined and illustrated with case histories.
Assuntos
Assistência Ambulatorial , Prestação Integrada de Cuidados de Saúde , Doença de Huntington/terapia , Planejamento de Assistência ao Paciente , Atividades Cotidianas , Humanos , Doença de Huntington/diagnóstico , Avaliação das Necessidades , Países Baixos , Casas de Saúde , Apoio Social , Inquéritos e Questionários , Recursos HumanosRESUMO
OBJECTIVES: To study metabolic brain changes in preclinical carriers of Huntington disease (PreHD) using proton magnetic resonance spectroscopy (1H-MRS) and to examine their relationship to neuropsychological performance. METHODS: Seventeen subjects with PreHD and 17 controls, matched for age and education, were studied. Frontal cortex and basal ganglia 1H-MRS, and a detailed neuropsychological battery, including visuomotor integration and speed, and memory, frontal, and visuospatial tests were performed. Statistical analysis included Student t-test and Pearson correlations (significance p < 0.05). RESULTS: Frontal choline-containing compounds (CHO) were decreased in PreHD [t (32) = -2.834, p = 0.008]. Subjects with PreHD performed worse than controls in the 15-Objects test [t (32) = 4.077, p = 0.000], Luria motor alternances [t (32) = -2.094, p = 0.044], and Symbol Digit tests [t (32) = -2.136, p = 0.040]. Decreased frontal CHO in PreHD correlated to slowing in visuomotor tasks (the 15-Objects test: r = -0.60, p = 0.000, and the Symbol Digit: r = 0.37, p = 0.047). CONCLUSION: As choline-containing compounds relate to membrane turnover, membrane dysfunction antedating neuronal death is suggested to occur in the frontal cortex in preclinical carriers of Huntington disease. This dysfunction may be responsible for some of the neuropsychological deficits observed.
Assuntos
Colina/metabolismo , Transtornos Cognitivos/metabolismo , Cognição , Lobo Frontal/metabolismo , Doença de Huntington/metabolismo , Doença de Huntington/psicologia , Adulto , Gânglios da Base/metabolismo , Gânglios da Base/patologia , Gânglios da Base/fisiopatologia , Membrana Celular/metabolismo , Membrana Celular/patologia , Colina/análise , Cognição/fisiologia , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/fisiopatologia , Regulação para Baixo/fisiologia , Feminino , Lobo Frontal/patologia , Lobo Frontal/fisiopatologia , Humanos , Doença de Huntington/diagnóstico , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Masculino , Lipídeos de Membrana/metabolismo , Pessoa de Meia-Idade , Degeneração Neural/diagnóstico , Degeneração Neural/metabolismo , Degeneração Neural/fisiopatologia , Neurônios/metabolismo , Neurônios/patologia , Testes Neuropsicológicos , Valor Preditivo dos Testes , Desempenho Psicomotor/fisiologiaRESUMO
Serial high-resolution structural magnetic resonance imaging scans of the brain can now be precisely aligned, with six degrees of freedom (three mutually orthogonal translational and three rotational degrees of freedom around three mutually orthogonal axes), using a rigid-body subvoxel registration technique. This is driven by the in-plane point spread function for images acquired in the Fourier domain with data obtained over a bounded region of k-space, namely the sinc interpolation function, where sinc z = (sin z)/z, with z being any complex number (including zero). Computational subtraction of the three-dimensional Cartesian spatial representation matrices of serially acquired scan data allows for the determination of structural cerebral changes with great precision, since voxel signals from unchanged structures are almost completely cancelled. Thus changes readily show up against a background of noise. Furthermore, lateral ventricular changes can now be accurately quantified using a semi-automated method involving contour production, threshold computation, binary image creation and ventricular extraction. These techniques have been applied to the investigation of the effects on cerebral structure of intervention with fatty acids, particularly the long-chain polyunsaturated n-3 fatty acid eicosapentaenoic acid (EPA), in disorders such as schizophrenia, treatment-resistant depression, chronic fatigue syndrome (myalgic encephalomyelitis or ME), and Huntington's disease.
Assuntos
Encéfalo/efeitos dos fármacos , Transtorno Depressivo/tratamento farmacológico , Síndrome de Fadiga Crônica/tratamento farmacológico , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Insaturados/administração & dosagem , Doença de Huntington/tratamento farmacológico , Aumento da Imagem/métodos , Processamento de Imagem Assistida por Computador/métodos , Imageamento por Ressonância Magnética/métodos , Esquizofrenia/tratamento farmacológico , Atrofia , Encéfalo/patologia , Transtorno Depressivo/diagnóstico , Ácido Eicosapentaenoico , Síndrome de Fadiga Crônica/diagnóstico , Seguimentos , Humanos , Doença de Huntington/diagnóstico , Plasticidade Neuronal/efeitos dos fármacos , Plasticidade Neuronal/fisiologia , Esquizofrenia/diagnóstico , Sensibilidade e EspecificidadeRESUMO
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide (CAG) repeat on the huntingtin gene. Neurodegeneration in HD affects most prominently the basal ganglia. Therefore, diffusivity was obtained in the basal ganglia and thalamus of 29 patients with early HD and 27 healthy volunteers by means of the trace of the diffusion tensor (Trace(D)). Putaminal, caudate, pallidal, and thalamic Trace(D) values were increased in patients with HD compared with controls. Increased diffusivity in the putamen and caudate nucleus correlated with global functional impairment, CAG repeat length, as well as bicaudate ratio. Diffusion-weighted imaging appears to be a promising surrogate marker for disease severity in HD. Sensitivity to change remains to be established longitudinally.
Assuntos
Imagem de Difusão por Ressonância Magnética , Doença de Huntington/diagnóstico , Processamento de Imagem Assistida por Computador , Imageamento por Ressonância Magnética , Atividades Cotidianas/classificação , Adulto , Idoso , Gânglios da Base/patologia , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência , Índice de Gravidade de Doença , Tálamo/patologiaRESUMO
This paper discusses the main ethical issues that arise when testing for genetic diseases with a late adult onset, such as Huntington's disease, take place. It is imperative to study genetic testing for HD and similar diseases because of the potential to influence future medical advances and the growing number of individuals who are considered pre-symptomatic. The main ethical issues are consent and privacy, prenatal testing and its implications, in addition to insurance discrimination. These issues are viewed from the perspective of genetic counselors, patients, the families of patients, and insurance companies. Policies put forth by the United States National Society of Genetic Counselors ("NSGC"), the Task Force on Genetic Testing, and the President's Council for Bioethics are also analyzed. Finally, new recommendations are proposed in order to ameliorate the ethical dilemmas encountered in genetic testing. These recommendations are largely based on existing policies and therefore involve amending current policies rather than revamping them.